9 sources checked · 2 source groups included · 15m ago
Still Watching
Personalized m RNA cancer vaccine shows promise in extending life span in melanoma trial
CBS News and The Sydney Morning Herald describe the same event in different terms.
2 Left7 Center0 Right
Still watching.Optics is waiting for a cleaner match before calling the split.
STILL WATCHING
As of August 19, 2026 at 10:16 PM, this is how Optics News reads the wording differences in this story.
What happenedMerck and Moderna announced Wednesday that a personalized m RNA-based cancer vaccine succeeded in a large, late-stage trial among high-risk patients with melanoma.
The headline splitThe left frames it as "Dr. Oz on Trump and prescription drug prices, skin cancer vaccine trial". The center frames it as "Moderna shares nearly triple on skin cancer vaccine success".
Match confidenceMedium confidence. 9 sources across 2 bias buckets. Useful framing signal — check the source list before sharing.
Same-event confidenceMedium
9 sources across 2 bias buckets agree on the event.
Framing confidenceModerate
64/99 — meaningful wording shift across the spectrum.
WHAT EACH SIDE EMPHASIZED
Left / center-leftDr. Oz on Trump and prescription drug prices, skin cancer vaccine trial
CBS News · Center-left · News report
CenterPersonalized m RNA cancer vaccine shows promise in extending life span in melanoma trial
KABC / ABC7 Los Angeles · Center · News report
Right / center-rightNo matching source in this bucket yet.
Personalized m RNA cancer vaccine shows promise in extending life span in melanoma trial
Merck and Moderna announced Wednesday that a personalized m RNA-based cancer vaccine succeeded in a large, late-stage trial among high-risk patients with melanoma.
Dr. Oz on Trump and prescription drug prices, skin cancer vaccine trial
Dr. Mehmet Oz, administrator of the Centers for Medicare and Medicaid Services, joins "The Takeout" to discuss the Trump administration's touting of lower prescription drug prices. He also...
‘Landmark’: New m RNA vaccine could prevent skin cancer from returning, companies say
Moderna and Merck said the personalised vaccine reduced the risk of recurrence and spread of melanoma in a late-stage trial, a major success in a new field of cancer treatment.
‘Landmark’: New m RNA vaccine could prevent skin cancer from returning, companies say
Moderna and Merck said the personalised vaccine reduced the risk of recurrence and spread of melanoma in a late-stage trial, a major success in a new field of cancer treatment.
